Production of Ergot Alkaloids "$!
The earliest procedures used for extraction were designed to obtain alkaloids
from sclerotia. In general the sclerotia would be dried, powdered, alkalinized, and
extracted with tartaric acid. For further purification, the tartaric acid solution was
made alkaline and extracted with chloroform. This chloroform layer would then
contain all the alkaloids. This has led to the terms water-soluble alkaloids which
include the simple amide lysergic acid derivatives and the clavines, whereas the
water-insoluble alkaloids now include the peptide-type. Nowadays the method
adopted for both water-soluble and water-insoluble peptides is to extract the
powdered ergot with chloroform to which a small amount of methanolic ammonia
has been added. The chloroform extract is concentrated to a small volume, diluted
with ether and extrated with concentrated H
2
SO
4
. On neutralization with
ammonia the water-soluble alkaloids can be extracted with water and the water-
insoluble ones with carbon-tetrachloride.
SUGGESTED READINGS
Boichenko, L.V., Boichenko, D.M., Vinokurova, N.G., Reshetilova, T.A., Arinbasarov, M.U. 2001.
Screening for Ergot Alkaloid Producers among Microscopic Fungi by Means of the
Polymerase Chain Reaction, Microbiology, 70: 306-307.
Dongen, van P.W.J., de Groot, A.N.J.A. 1995. History of ergot alkaloids from ergotism to
ergometrine, European Journal of Obstetrics & Gynaecology and Reproductive Biology, 60:
109-116.
Evans, W.C. 1996. Pharmacognosy. 14
th
ed, W B Saunders Company Ltd, London, UK.
Groot, N.J.A. de Akosua, van Dongen, Pieter W.J, Vree, Tom, B., Hekster, Yechiel A., van
Roosmalen, Jos. 1998. Ergot Alkaloids - Current Status and Review of Clinical Pharmacology
and Therapeutic Use Compared with Other Oxytoxics in Obstretrics and Gynaecology, Drugs,
56: 525-8.
Hardman, J.G., Limbird, L.E. (eds) 1996. The Pharmacological Basis of Therapeutics, 9
th
ed,
McGraw-Hill
Kobel, H., Kobel, J. 1986. Ergot alkaloids. In: Biotechnology, H.J., Rehm, G. Reed, (eds) Vol 4,. 2nd
Ed. VCH, Weinheim, Germany, pp. 569-609.
Komarova, E.L., Tolkachev, O.N. 2001. The Chemistry of Peptide Ergot Alkaloids,
Pharmaceutical Chemistry Journal, 35: 504-506.
Lange, Klaus W. 1998. Clinical Pharmacology of Dopamine Agonists in Parkinson’s Disease,
Drugs & Aging, 13: 385-386.
Langley, D. 1998. Exploiting the Fungi: Novel Leads to New Medicines, Mycologist, 11: 165-166.
Menge, J.M.M. 2000. Progress and Prospects of Ergot Alkaloid Research. Advances in
Biochemical Engineering/Biotechnology. 68, 1-20.
Thompson, F., Muir, A., Stirton, J., Macphee, G., Hudson, S. 2001. Parkinson’s Disease, The
Pharmaceutical Journal, 267: 600-612.
Votruba, V., Flieger, M. 2000. Separation of Ergot Alkaloids by Adsorption on Silicates,
Biotechnology Letters, 22: 1281-1282.
Rehacek, Z., Sajdl, P. 1990. Ergot Alkaloids: Chemistry, Biological Effects, Biotechnology.
Academia Praha: Czech Republic.